Vegenics Limited
Records under this name other than the patents Vegenics Limited holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,896,499 | Growth factor antagonists for organ transplant alloimmunity and arteriosclerosis Formerly held In force · USPTO record | In force | USPTO record | |
| US 8,025,886 | Modified VEGF-A with improved angiogenic properties Formerly held In force · USPTO record | In force | USPTO record | |
| US 9,073,997 | Growth factor antagonists for organ transplant alloimmunity and arteriosclerosis Formerly held In force · USPTO record | In force | USPTO record | |
| US 8,940,695 | Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy Formerly held Term ended Term ended Nov 10, 2026 · Medium confidence | Term ended | Term ended Nov 10, 2026 | Medium confidence |
| US 7,846,437 | Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same Formerly held Term ended Term ended Mar 7, 2025 · USPTO record | Term ended | Term ended Mar 7, 2025 | USPTO record |
| US 7,307,107 | Photopolymerizable Composition and Use Thereof Term ended Term ended Mar 11, 2024 · High confidence | Term ended | Term ended Mar 11, 2024 | High confidence |
| US 7,534,572 | Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue Formerly held Lapsed on the fee record Ended May 19, 2021 · USPTO record | Lapsed on the fee record | Ended May 19, 2021 | USPTO record |
| US 6,383,484 | Antibodies to truncated VEGF-D and thereof Term ended Term ended Dec 21, 2019 · USPTO record | Term ended | Term ended Dec 21, 2019 | USPTO record |
| US 7,871,798 | Mammalian cells that express VEGF-D polypeptides Formerly held Term ended Term ended Mar 24, 2019 · USPTO record | Term ended | Term ended Mar 24, 2019 | USPTO record |
| US 7,410,639 | Vascular endothelial growth factor D(VEGF-D) antibodies and methods of use Formerly held Term ended Term ended Mar 21, 2019 · USPTO record | Term ended | Term ended Mar 21, 2019 | USPTO record |